Biofrontera Inc.
BFRI
$0.7874
-$0.0136-1.70%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 18.53% | 1.30% | 34.05% | -9.40% | 4.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.53% | 1.30% | 34.05% | -9.40% | 4.46% |
| Cost of Revenue | -1.79% | 6.25% | 50.35% | -10.48% | 2.13% |
| Gross Profit | 39.38% | -3.97% | 18.14% | -8.20% | 6.96% |
| SG&A Expenses | -9.32% | -3.07% | -30.54% | 6.17% | -2.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.31% | 4.93% | -9.97% | 0.54% | -0.91% |
| Operating Income | 55.71% | -12.22% | 40.28% | -19.52% | 13.15% |
| Income Before Tax | -139.74% | 10.65% | 97.59% | -39.65% | 226.44% |
| Income Tax Expenses | 50.00% | 200.00% | 42.86% | -80.00% | -700.00% |
| Earnings from Continuing Operations | -139.59% | 10.61% | 97.39% | -39.57% | 226.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -139.59% | 10.61% | 97.39% | -39.57% | 226.61% |
| EBIT | 55.71% | -12.22% | 40.28% | -19.52% | 13.15% |
| EBITDA | 55.13% | -12.51% | 40.94% | -20.06% | 13.53% |
| EPS Basic | -111.20% | 78.84% | 99.30% | 48.58% | 176.54% |
| Normalized Basic EPS | 73.92% | 65.87% | 99.27% | -3.19% | 43.77% |
| EPS Diluted | -122.43% | 78.84% | 99.30% | 48.58% | 176.49% |
| Normalized Diluted EPS | 73.92% | 65.87% | 99.27% | -3.19% | 43.77% |
| Average Basic Shares Outstanding | 253.49% | 322.45% | 274.18% | 171.43% | 65.42% |
| Average Diluted Shares Outstanding | 253.49% | 322.45% | 274.18% | 171.43% | 65.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
